Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018102769) TREATMENT OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/102769 International Application No.: PCT/US2017/064339
Publication Date: 07.06.2018 International Filing Date: 01.12.2017
IPC:
A61K 31/4745 (2006.01) ,A61K 31/724 (2006.01) ,A61K 47/61 (2017.01) ,A61K 39/395 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4738
ortho- or peri-condensed with heterocyclic ring systems
4745
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
715
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
716
Glucans
724
Cyclodextrins
[IPC code unknown for A61K 47/61]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
BLUELINK PHARMACEUTICALS, INC. [US/US]; 2503 S Loop Dr. Ames, IA 50010, US
Inventors:
FRIEDMAN, Paul; US
ELIASOF, Scott; US
SENDEROWICZ, Adrian; US
TELLEZ, Andres; US
LAZARUS, Douglas; US
JAYARAMAN, Lata; US
Agent:
LARKIN, Angelyn; US
Priority Data:
62/428,90801.12.2016US
Title (EN) TREATMENT OF CANCER
(FR) TRAITEMENT DU CANCER
Abstract:
(EN) Provided are methods relating to the treatment of cancer with a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101 in combination with an inhibitor of the tryptophan metabolism pathway, e.g., an indoleamine-2,3-dioxygenase (IDO) inhibitor or a tryptophan-2, 3 -dioxygenase (TDO) inhibitor.
(FR) L'invention concerne des procédés se rapportant au traitement du cancer avec un inhibiteur de CDP-topo-isomérase, par exemple, un conjugué CDP-camptothécine ou de dérivé de camptothécine, par exemple, CRLX101 en combinaison avec un inhibiteur de la voie du métabolisme du tryptophane, par exemple un inhibiteur de l'indoléamine-2,3-dioxygénase (IDO) ou un inhibiteur de la tryptophane-2,3-dioxygénase (TDO).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)